KIVI Boise: New research tracks how bacteria communicate, share DNA to resist antibiotics

BOISE – A growing public health crisis is happening all over the world, including our rivers, soil, and hospitals here in Idaho.

“We’ve used tons and tons of antibiotics lately, these bacteria that are resistant are rising in frequency everywhere on the planet basically,” said University of Idaho Professor Eva top, “we’re traveling much more, so if something pops up in China or India, the next day or week it can be in the U.S. or Europe or wherever.”

Read more:

Medgadget ft. Nu-Med Plus: Miniaturized Inhaled Nitric Oxide Delivery Units for Use in a Doctor’s Office

Nu-Med Plus, a medtech firm based in Utah, has developed a range of smart delivery devices for inhaled nitric oxide delivery, including a miniaturized unit that can operate in a doctor’s office. The innovation has been possible as parts of the drug patent for nitric oxide have been invalidated, meaning that the cost of the treatment could come down.

Read more:

HOW TO LIVE TO 200 PODCAST features Dr. Ivan Liachko of Phase Genomics, ‘Cat Poop and the Secrets of the Microbiome’

Dr. Ivan Liachko, Founder & CEO of Phase Genomics, recently sat down with the How to Live to 200 Podcast to discuss his research including microbiomes, cat poop, genomics and key insights to help you live healthier and longer.

Listen to the podcast here.

Study to explore viability of robot-built space outposts made from debris

There’s a lot of perfectly good space junk floating around up there, such as the upper stages of spent rockets. NanoRacks, a company dedicated to democratizing low-earth orbit by supporting innovations like cheap, easily deployed CubeSats, wants to use those in-space structures to build habitats known as Outposts. The Outposts could prove to be crucial infrastructure for commercial space travel and exploration.

Naturally, the heavy lifting — er, weightless shifting — will fall to robots.

Sounds a little far-fetched, to be sure, but NASA is getting behind the idea. The space agency recently chose NanoRacks as one of 13 companies involved in a study of commercial human spaceflight in Low Earth Orbit (LEO). This week, NanoRacks shared some details about its Space Outpost Program and identified strategic study partners supporting its efforts, including Olis Robotics, which makes remote robotics software.

Read more here:

Seattle Angel Fund rebrands with launch of SeaChange, its largest raise to date

Angel investing is a tricky game. Supporting a startup just getting off the ground takes a lot of work. But after several years spent as a venture capitalist in the Bay Area, Susan Preston, now the managing member at Seattle’s SeaChange Fund, returned to the Pacific Northwest with an idea for how to spot sound bets for seed investments and then nurture their growth.

And a collaborative due diligence process aimed at both fostering consensus among angel investors and encouraging entrepreneurs is at its heart.

Read more about SeaChange’s transformation here:

GeekWire: SEngine Receives 3.1m Grant to Bring Personalized Cancer Fighting Tech to Patients

Every patient’s cancer is unique and every patient responds to cancer drugs differently. But right now, all patients with the same kind of cancer are treated with the same drugs.

SEngine Precision Medicine is hoping to change that with new platform, called PARIS, that grows and analyzes a patient’s cancer cells to figure out which drugs will work best for them.

Read the rest right here:

s2s PR Representing Xconomy “What’s Hot in Seattle Biotech” Speakers

We’re proud to have cultivated the speaking engagement for Phase Genomics. CEO Ivan Liachko will present on the convergence of technology and the life sciences on June 12th in Seattle, alongside other biotech innovators such as Adaptive Biotechnologies and Silverback Therapeutics.

Find the details and join us here:



SEngine Discovery of Common Link in 28% of all Cancers Makes Medical, Life Science News

Scientists from Cure First and SEngine Precision Medicine discover common link in 28% of all cancers

Read the story here